This page has only limited features, please log in for full access.

Prof. Suresh Varma Kuchipudi
Department of Veterinary and Biomedical Sciences, Penn State University, Wiley Lane, University Park, PA 16802-1110, USA

Basic Info

Basic Info is private.

Research Keywords & Expertise

0 Viral Pathogenesis
0 Zoonotic and emerging viruses
0 Diagnostic assay development
0 Immune responses to viruses
0 Viral vaccines and anti-virals

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Preprint content
Published: 21 August 2020
Reads 0
Downloads 0

The optimal timeframe for donating convalescent plasma to be used for COVID-19 immunotherapy is unknown. To address this important knowledge deficit, we determinedin vitrolive-virus neutralizing capacity and persistence of IgM and IgG antibody responses against the receptor-binding domain and S1 ectodomain of the SARS-CoV-2 spike glycoprotein in 540 convalescent plasma samples obtained from 175 COVID-19 plasma donors for up to 142 days post-symptom onset. Robust IgM, IgG, and viral neutralization responses to SARS-CoV-2 persist, in the aggregate, for at least 100 days post-symptom onset. However, a notable acceleration in decline in virus neutralization titers ≥160, a value suitable for convalescent plasma therapy, was observed starting 60 days after first symptom onset. Together, these findings better define the optimal window for donating convalescent plasma useful for immunotherapy of COVID-19 patients and reveal important predictors of an ideal plasma donor, including age and COVID-19 disease severity score. One Sentence Summary Evaluation of SARS-CoV-2 anti-spike protein IgM, IgG, and live-virus neutralizing titer profiles reveals that the optimal window for donating convalescent plasma for use in immunotherapy is within the first 60 days of symptom onset.

ACS Style

Abhinay Gontu; Sreenidhi Srinivasan; Eric Salazar; Meera Surendran Nair; Ruth H. Nissly; Denver Greenawalt; Ian M. Bird; Catherine Herzog; Matthew J. Ferrari; Indira Poojary; Robab Katani; Scott E. Lindner; Allen M. Minns; Randall Rossi; Paul A. Christensen; Brian Castillo; Jian Chen; Todd N. Eagar; Xin Yi; Picheng Zhao; Christopher Leveque; Randall J. Olsen; David W. Bernard; Jimmy Gollihar; Suresh V. Kuchipudi; James M. Musser; Vivek Kapur. Limited window for donation of convalescent plasma with high live-virus neutralizing antibodies for COVID-19 immunotherapy. 2020, 1 .

AMA Style

Abhinay Gontu, Sreenidhi Srinivasan, Eric Salazar, Meera Surendran Nair, Ruth H. Nissly, Denver Greenawalt, Ian M. Bird, Catherine Herzog, Matthew J. Ferrari, Indira Poojary, Robab Katani, Scott E. Lindner, Allen M. Minns, Randall Rossi, Paul A. Christensen, Brian Castillo, Jian Chen, Todd N. Eagar, Xin Yi, Picheng Zhao, Christopher Leveque, Randall J. Olsen, David W. Bernard, Jimmy Gollihar, Suresh V. Kuchipudi, James M. Musser, Vivek Kapur. Limited window for donation of convalescent plasma with high live-virus neutralizing antibodies for COVID-19 immunotherapy. . 2020; ():1.

Chicago/Turabian Style

Abhinay Gontu; Sreenidhi Srinivasan; Eric Salazar; Meera Surendran Nair; Ruth H. Nissly; Denver Greenawalt; Ian M. Bird; Catherine Herzog; Matthew J. Ferrari; Indira Poojary; Robab Katani; Scott E. Lindner; Allen M. Minns; Randall Rossi; Paul A. Christensen; Brian Castillo; Jian Chen; Todd N. Eagar; Xin Yi; Picheng Zhao; Christopher Leveque; Randall J. Olsen; David W. Bernard; Jimmy Gollihar; Suresh V. Kuchipudi; James M. Musser; Vivek Kapur. 2020. "Limited window for donation of convalescent plasma with high live-virus neutralizing antibodies for COVID-19 immunotherapy." , no. : 1.